Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 544

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Dronedarone in High-Risk Permanent Atrial Fibrillation

Open access
Connolly, Stuart J., Camm, A. John, Halperin, Jonathan L., Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Álvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B., Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S., Merino, Jose L., Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S., Sim, Kui-Hian, Stiles, Martin K., Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, Hohnloser, Stefan H. · 2011 · New England Journal of Medicine

Abstract

BACKGROUND: Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation. It also lowers heart rate and blood pressure and has antiadrenergic and potential ventricular antiarrhythmic effects. We hypothesized that dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation. METHODS: We assigned patients who were at least 65 years of age with at least a 6-month history of permanent atrial fibrillation and risk factors for major vascular events to receive dronedarone or placebo. The first coprimary outcome was stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death. RESULTS: After the enrollment of 3236 patients, the study was stopped for safety reasons. The first coprimary outcome occurred in 43 patients receiving dronedarone and 19 receiving placebo (hazard ratio, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P=0.002). There were 21 deaths from cardiovascular causes in the dronedarone group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P=0.046), including death from arrhythmia in 13 patients and 4 patients, respectively (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P=0.03). Stroke occurred in 23 patients in the dronedarone group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P=0.02). Hospitalization for heart failure occurred in 43 patients in the dronedarone group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P=0.02). CONCLUSIONS: Dronedarone increased rates of heart failure, stroke, and death from cardiovascular causes in patients with permanent atrial fibrillation who were at risk for major vascular events. Our data show that this drug should not be used in such patients. (Funded by Sanofi-Aventis; PALLAS ClinicalTrials.gov number, NCT01151137.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1109867

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

Metadata

Authors
Connolly, S. J., Camm, A. J., Halperin, J. L., Joyner, C., Alings, M., Amerena, J., Atar, D., Avezum, Á., Blomström, P., Borggrefe, M., Budaj, A., Chen, S.-A., Ching, C. K., Commerford, P., Dans, A., Davy, J.-M., Delacrétaz, E., Di Pasquale, G., Diaz, R., Dorian, P., Flaker, G., Golitsyn, S., Gonzalez-Hermosillo, A., Granger, C. B., Heidbüchel, H., Kautzner, J., Kim, J. S., Lanas, F., Lewis, B. S., Merino, J. L., Morillo, C., Murin, J., Narasimhan, C., Paolasso, E., Parkhomenko, A., Peters, N. S., Sim, K.-H., Stiles, M. K., Tanomsup, S., Toivonen, L., Tomcsányi, J., Torp-Pedersen, C., Tse, H.-F., Vardas, P., Vinereanu, D., Xavier, D., Zhu, J., Zhu, J.-R., Baret-Cormel, L., Weinling, E., Staiger, C., Yusuf, S., Chrolavicius, S., Afzal, R., & Hohnloser, S. H.
Venue
New England Journal of Medicine
Published
2011-12-15
Volume
365
Issue
24
Pages
2268-2276
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2121512872
Cited by
544
References
16
FWCI
48.19
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.